We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bond Kinetics Underlie von Willebrand's Disease

By Biotechdaily staff writers
Posted on 08 Jul 2002
A study has shown that the exceptional persistence of temporary chemical bonds between blood platelets and the von Willebrand factor (vWF) clotting protein underlies the bleeding disorder known as type IIb von Willebrand's disease. More...
The results, published in the July 2002 issue of Biophysical Journal, suggest that the disease occurs because a defective form of vWF allows vWF-platelet complexes to last longer than they should.

Until recently it was thought that substitution of one amino acid in defective vWF caused a conformational change that stabilized the bond between the protein and platelets. The findings of the current study support a different explanation, however. Investigators from the Washington University School of Medicine (St. Louis, MO, USA) found that bond kinetics, the rate at which chemical bonds form and dissociate, rather than a conformational change, is responsible.

"This is the first time that a naturally occurring disease has been linked to an alteration in the kinetic properties of a chemical bond,” explained study leader Dr. Thomas G. Diacovo, assistant professor of pediatrics, pathology, and immunology. "The finding should give us a better understanding of how normal platelets function and of the delicate balance that exists between these blood-clotting elements. Disturb that balance, and the whole system falls apart.”

The importance of bond kinetics had previously been demonstrated for a family of proteins called selectins, which are involved in the recruiting of white blood cells to inflamed blood vessel walls. Working with platelets in the current study, the researchers found that in normal individuals a few transient bonds form between circulating platelets and vWF. In type IIb von Willebrand's disease, however, the bonds last significantly longer than normal. That extra time allows many additional bonds to form, which stabilizes the interaction.

"It is not just a brief touch-and-go,” said Dr. Diacovo. "Rather, one bond forms and before it breaks, two, three, and four more have formed.” As more bonds form, small aggregates of platelets and vWF develop. These aggregates are removed from the blood, which reduces the amount of vWF and the number of platelets in circulation. Consequently, people with von Willebrand's disease have a mild-to-moderate bleeding disorder. They bruise easily and simple nosebleeds can continue for several hours or days before finally healing.


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.